Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus.

ABSTRACT:

Aim

Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control.

Materials & methods

Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A_1c (HbA_1c) and glucose measures over time.

Results

Mean HbA_1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02).

Conclusion

Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patie

SUBMITTER: Karlin NJ 

PROVIDER: S-EPMC6426167 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature